IMR Press / EJGO / Volume 36 / Issue 6 / DOI: 10.12892/ejgo2707.2015

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
BEP for high-risk gestational trophoblastic tumor: results from a cohort of 45 patients
Show Less
1 Department of s Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan
2 Chengdu First People’s Hospital, Chengdu, Sichuan
3 Department of Ultrasound, Sichuan Cancer Hospital, Chengdu, Sichuan (China)
These authors contributed equally.
Eur. J. Gynaecol. Oncol. 2015, 36(6), 726–729;
Published: 10 December 2015

Aim: To evaluate the effectiveness and safety of combination chemotherapy of bleomycin, etoposide, and cisplatin (BEP) regimen in patients with high-risk gestational trophoblastic neoplasia (GTN). Materials and Methods: The authors analyzed the clinical response, toxicity, and the occurrence of secondary tumors of 45 patients with high-risk GTN under BEP. Results: The total complete remission (CR) rate of BEP regimen was 88.89% (40/45). Five patients developed drug-resistance after average 4.8 courses of BEP, and the regimen converted to etoposide, methotrexate, and dactinomycin (EMA) / cyclophosphamide and vincristine sulfate (CO). Ultimately, four cases achieved CR and one case died of cancer. There were no severe anaphylaxis and obvious impairment of cardiac, liver, pulmonary and kidney function, except one patient who developed grade IV bone marrow suppression and worsened pulmonary fibrosis after chemotherapy. None of survival patients developed secondary tumor during the follow-up. Conclusion: For young high-risk GTN patients, BEP may represent a safe and effective regimen.
High-risk gestational trophoblastic neoplasia
BEP regimen
Adverse reaction of chemotherapy
Back to top